Combining oncolytic virus and radiation therapy for cancer management

Abstract

Cancer has caused a tremendous burden in developing countries. Oncolytic virus (OV) therapy is an emerging modality with the potential to be a single or combination agent with radiation therapy (RT). Following entry of OV to the cell, OV will replicate and assemble before exiting from tumor cells. Construction of OV can be done by modifying the capsid, genome, and chemical material of viruses. Irradiation will induce double-strand breaks, and further integration of OV with DNA damage response pathway will interact with the MRE11-Rad50-Nbs1 complex to regulate the mobilization of E4 open reading frame 6, protein phosphatase 2A, poly(ADP-ribose) polymerase, apoptosis-inducing factor, and topoisomerase-IIβ-binding protein 1. Degradation of DNA-dependent protein kinase catalytic subunits via human simplex virus-1-infected cell polypeptide 0 will inhibit DNA repair. OV and RT have a synergistic interaction to cause viral oncolysis and upregulation of immune response. In the clinical setting, most studies have demonstrated that OV is a safe treatment with less toxicity. Moreover, OV + RT resulted in longer median survival (62.4 vs. 37.7 weeks) in malignant glioma.

Keywords

Oncolytic virus / radiation therapy / cancer / developing country

References

[1] Torre LA,Ward EM.Global cancer incidence and mortality rates and trends-an update.Cancer Epidemiol Biomarkers Prev2016;25:16-27

[2] Global Cancer Observatory. International agency for research on cancer-WHO. Available from: https://gco.iarc.fr/ [Last accessed on 24 Apr 2022]

[3] Baskar R.Radiation therapy and cancer control in developing countries: Can we save more lives?.Int J Med Sci2017;14:13-7 PMCID:PMC5278654

[4] Wang JJ,Han F.Tumor microenvironment: recent advances in various cancer treatments.Eur Rev Med Pharmacol Sci2018;22:3855-64

[5] Denton NL,Scott TR.Tumor-associated macrophages in oncolytic virotherapy: friend or foe?.Biomedicines2016;4:13 PMCID:PMC5344259

[6] Reale A,Conciatori V,Calistri A.Perspectives on immunotherapy via oncolytic viruses.Infect Agent Cancer2019;14:5 PMCID:PMC6371415

[7] Touchefeu Y,Harrington KJ.Oncolytic viruses in radiation oncology.Radiother Oncol2011;99:262-70

[8] Zheng M,Tong A.Oncolytic viruses for cancer therapy: barriers and recent advances.Mol Ther Oncolytics2019;15:234-47 PMCID:PMC6911943

[9] Dobosz P.The intriguing history of cancer immunotherapy.Front Immunol2019;10:2965 PMCID:PMC6928196

[10] Choi AH,Fong Y.From benchtop to bedside: a review of oncolytic virotherapy.Biomedicines2016;4:18 PMCID:PMC5344257

[11] Coffin RS.From virotherapy to oncolytic immunotherapy: where are we now?.Curr Opin Virol2015;13:93-100

[12] Raja J,Gettinger SN,Kim HS.Oncolytic virus immunotherapy: future prospects for oncology.J Immunother Cancer2018;6:140 PMCID:PMC6280382

[13] Brown CW.Oncolytic viruses: a new weapon to fight cancer.J Med Imaging Radiat Sci2008;39:115-27

[14] Ylösmäki E.Design and application of oncolytic viruses for cancer immunotherapy.Curr Opin Biotechnol2020;65:25-36

[15] Russell L,Russell SJ.Oncolytic viruses: priming time for cancer immunotherapy.BioDrugs2019;33:485-501 PMCID:PMC6790338

[16] Lawler SE,Cho CF.Oncolytic viruses in cancer treatment: a review.JAMA Oncol2017;3:841-9

[17] Twumasi-Boateng K,Kwok YYE,Nelson BH.Oncolytic viruses as engineering platforms for combination immunotherapy.Nat Rev Cancer2018;18:419-32

[18] Vens C,Wouters BG. Irradiation-induced damage and the DNA damage response. Available from: https://books.google.com.hk/books?hl=zh-CN&lr=&id=kF0PEAAAQBAJ&oi=fnd&pg=PA9&dq=Vens+C,+Koritzinsky+M,+Wouters+BG.+Irradiation-induced+damage+and+the+DNA+damage+response.+&ots=ARYOthDq28&sig=m67oM7IkReo652u9OFrDXsG4Oic&redir_esc=y#v=onepage&q&f=false [Last accessed on 24 Apr 2022]

[19] O’Cathail SM,Maughan TS,Seymour LW.Combining oncolytic adenovirus with radiation-a paradigm for the future of radiosensitization.Front Oncol2017;7:153 PMCID:PMC5523729

[20] Petrini J.The cellular response to DNA double-strand breaks: defining the sensors and mediators.Trends in Cell Biology2003;13:458-62

[21] Chaurushiya MS.Viral manipulation of DNA repair and cell cycle checkpoints.DNA Repair (Amst)2009;8:1166-76 PMCID:PMC2725192

[22] Bugreev DV,Mazin AV.Rad54 protein promotes branch migration of Holliday junctions.Nature2006;442:590-3

[23] Park HU,Chung JH.Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G2 arrest mediated by Chk1.Oncogene2004;23:4966-74

[24] Durkin SS,Fryrear KA.HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase.J Biol Chem2008;283:36311-20 PMCID:PMC2605996

[25] Sun Y,Xu QZ.HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation.Int J Radiat Oncol Biol Phys2006;65:842-50

[26] Liu MT,Chen SC.Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells.Oncogene2004;23:2531-9

[27] Liu MT,Chen SC.Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity.Oncogene2005;24:2635-46

[28] DeBiasi RL,Meintzer S.Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis.J Virol2003;77:8934-47 PMCID:PMC167209

[29] Araujo FD,Carson CT,Weitzman MD.Adenovirus type 5 E4orf3 protein targets the Mre11 complex to cytoplasmic aggresomes.J Virol2005;79:11382-91 PMCID:PMC1193610

[30] Stracker TH,Weitzman MD.Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex.Nature2002;418:348-52

[31] Hart LS,Naczki C.The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner.J Biol Chem2005;280:1474-81

[32] Chowdhury D,Ishii H,Buratowski S.gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair.Mol Cell2005;20:801-9

[33] Forrester NA,Thomas A.Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection.J Virol2011;85:2201-11 PMCID:PMC3067775

[34] Blackford AN,Forrester NA.Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation.Proc Natl Acad Sci U S A2010;107:12251-6 PMCID:PMC2901489

[35] Lees-Miller SP,Kilvert MA,Rice SA.Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0.J Virol1996;70:7471-7 PMCID:PMC190814

[36] Parkinson J,Everett RD.Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase.J Virol1999;73:650-7 PMCID:PMC103871

[37] Hadjipanayis CG.Inhibition of DNA repair by a herpes simplex virus vector enhances the radiosensitivity of human glioblastoma cells.Cancer Res2005;65:5310-6

[38] Chiang CS,Wang SC.Irradiation promotes an m2 macrophage phenotype in tumor hypoxia.Front Oncol2012;2:89 PMCID:PMC3412458

[39] Vatner RE.Myeloid-derived cells in tumors: effects of radiation.Semin Radiat Oncol2015;25:18-27

[40] Gabrilovich DI,Bronte V.Coordinated regulation of myeloid cells by tumours.Nat Rev Immunol2012;12:253-68 PMCID:PMC3587148

[41] Hellström KE,Kant JA.Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population.J Exp Med1978;148:799-804 PMCID:PMC2184991

[42] North RJ.Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.J Exp Med1986;164:1652-66 PMCID:PMC2188446

[43] Schaue D,McBride WH.Cytokines in radiobiological responses: a review.Radiat Res2012;178:505-23 PMCID:PMC3723384

[44] Lugade AA,Gerber SA,Frelinger JG.Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.J Immunol2005;174:7516-23

[45] Lee Y,Wang Y.Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.Blood2009;114:589-95 PMCID:PMC2713472

[46] Gupta A,Vuong V.Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation.J Immunol2012;189:558-66

[47] Sharabi AB,Kochel CM.Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen.Cancer Immunol Res2015;3:345-55 PMCID:PMC4390444

[48] Garnett CT,Chakraborty M,Schlom J.Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.Cancer Res2004;64:7985-94

[49] Golden EB,Pellicciotta I,Helen Barcellos-Hoff M.Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.Oncoimmunology2014;3:e28518 PMCID:PMC4106151

[50] Apetoh L,Tesniere A.Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.Nat Med2007;13:1050-9

[51] Demaria S.Radiation as an immunological adjuvant: current evidence on dose and fractionation.Front Oncol2012;2:153 PMCID:PMC3481113

[52] Dyer A,Calderon H.Oncolytic Group B Adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators.Mol Ther Oncolytics2017;4:18-30 PMCID:PMC5363721

[53] Pokrovska TD,Puliyadi R.External beam radiation therapy and enadenotucirev: inhibition of the DDR and mechanisms of radiation-mediated virus increase.Cancers (Basel)2020;12:798 PMCID:PMC7226394

[54] Hirvinen M,Kapanen M.Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.Hum Gene Ther2015;26:134-44

[55] Ottolino-Perry K,Lichty BD,McCart JA.Intelligent design: combination therapy with oncolytic viruses.Mol Ther2010;18:251-63 PMCID:PMC2839289

[56] Egami T,Mizumoto K.Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake.Clin Cancer Res2008;14:1859-67

[57] Qian J,Dragovic AF,Lawrence TS.Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2.Cancer Res2005;65:5493-7

[58] Zhang M,Li J,Lawrence TS.Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts.Molecular Therapy2003;8:21-8

[59] Liu C,Petell CA.Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.Clin Cancer Res2007;13:7155-65

[60] Boland A,Opolon P.Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.Cancer Res2000;60:3484-92

[61] Faivre J,Gérolami R.Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats.Cancer Res2004;64:8045-51

[62] Gaut AW,Krager KJ,Trask DK.Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS).Head Neck2004;26:265-71

[63] Hallahan DE,Seung LP.Spatial and temporal control of gene therapy using ionizing radiation.Nat Med1995;1:786-91

[64] Manome Y,Wen PY,Kufe DW.Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine.Hum Gene Ther1998;9:1409-17

[65] Mundt AJ,Nemunaitis J.A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.Clin Cancer Res2004;10:5747-53

[66] Senzer N,Rosemurgy A.TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.J Clin Oncol2004;22:592-601

[67] Adusumilli PS,Chan MK.Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer.Ann Thorac Surg2005;80:409-16; discussion 416 PMCID:PMC1373787

[68] Bieler A,Holzmüller R.Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma.Radiother Oncol2008;86:419-27

[69] Chen Y,Dilley J,Li Y.CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.Cancer Res2001;61:5453-60

[70] Dilley J,Ko D,Rojas G.Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.Cancer Gene Ther2005;12:715-22

[71] Dilley J,Ko D.Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.Cancer Gene Ther2005;12:715-22

[72] Twigger K,White CL.Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.Clin Cancer Res2008;14:912-23

[73] Kim SH,Kooby DA.Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.Eur J Cancer2005;41:313-22

[74] Melief CJM,Garassino MC. Vaccines (dendritic cell vaccines, peptide vaccines, DNA vaccines, RNA vaccines, oncolytic viruses). Available from: https://ressources-aura.fr/wp-content/uploads/2020/01/2018-ESMO-Handbook-of-Immuno-Oncology.pdf [Last accessed on 24 Apr 2022]

[75] Immonen A,Tyynelä K.AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.Mol Ther2004;10:967-72

[76] Swisher SG,Komaki R.Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.Clin Cancer Res2003;9:93-101

[77] Freytag SO,Pegg J.Phase I study of replication-competent Adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.Cancer Res2003;63:7497-506

[78] Freytag SO,Aref I.Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer.Mol Ther2007;15:1016-23

[79] Freytag SO,Lu M.Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer.Int J Radiat Oncol Biol Phys2014;89:268-76 PMCID:PMC4026796

[80] Harrington KJ,Tanay MA.Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.Clin Cancer Res2010;16:4005-15

[81] Harrington KJ,Roulstone V.Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.Clin Cancer Res2010;16:3067-77 PMCID:PMC3907942

[82] Markert JM,Kuo HC.A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.Mol Ther2014;22:1048-55 PMCID:PMC4015243

[83] Mell LK,Daniels GA.Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma.Clin Cancer Res2017;23:5696-702

[84] U.S. National Library of Medicine. Oncolytic virus and radiation - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=oncolytic+virus+and+radiation&cntry=&state=&city=&dist= [Last accessed on 24 Apr 2022]

[85] Cattaneo R.How to develop viruses into anticancer weapons.PLoS Pathog2017;13:e1006190 PMCID:PMC5354445

[86] Lathwal A,Raghava GPS.OvirusTdb: a database of oncolytic viruses for the advancement of therapeutics in cancer.Virology. 2020:109-16